Vitamin D is important for bone health in the general population but the value of vitamin D supplementation, and the role of 25-hydroxyvitamin D independently of 1,25-dihydroxyvitmain D, in individuals with chronic kidney disease (CKD), particularly in those who require dialysis, remains uncertain. Supplementation may improve some biochemical parameters, such as reducing PTH levels in patients to CKD-stage 4 who have vitamin D deficiency; but it remains to be established whether the role of nutritional vitamin D in maintaining bone health in the general population can be extrapolated to the CKD population. There is currently insufficient evidence to recommend conclusively that nutritional vitamin D supplementation should be prescribed to individuals with CKD who have 25-hydroxyvitamin D deficiency, either for skeletal or non-skeletal health outcomes.
INTRODUCTION
Vitamin D is a key hormone for the maintenance of calcium and phosphate homeostasis. The term 'vitamin' is a misnomer, as Vitamin D is not an essential nutrient but is an endogenously produced classical hormone. 1 Vitamin D has endocrine, paracrine and autocrine actions at its canonical target tissues of the skeleton, gastrointestinal tract and kidney. However, the vitamin D receptor (VDR) is very widely expressed, suggesting a broader role for vitamin D beyond mineral homeostasis; and the role of vitamin D in non-classical target tissues has been the source of investigation.
Synthesis
Vitamin D has two distinct fat-soluble forms: vitamin D2 (ergocalciferol, synthesized by plants) and vitamin D3 (cholecalciferol, synthesized by animals). In mammals, cholecalciferol is synthesized in the skin by ultraviolet-B radiation of 7-dehydrocholesterol. Cholecalciferol undergoes hydroxylation in the liver to form 25-hydroxyvitamin D (or calcidiol), which is then hydroxylated by 1α-hydroxylase (CYP27B1) in the kidneys and other tissues to form water- 
Canonical and non-canonical roles of vitamin D
Classically, vitamin D, PTH and FGF23 act in concert to control bone mineral homeostasis. The main actions of vitamin D at the gut, kidney and bone ensure sufficient calcium and phosphate for bone mineralization and the prevention of rickets and osteomalacia (reviewed in 2 ). 1,25-dihydroxyvitamin D stimulates intestinal absorption of both calcium and phosphate. Intestinal calcium absorption occurs through both a saturable transcellular mechanism and a diffusional non-saturable process. 1,25-dihydroxyvitamin D enhances both processes, the first via regulation of several steps including calcium entry, intracellular diffusion and extrusion across the basolateral membrane; the second via induction of the calcium-binding protein calbindin. 1,25-dihydroxyvitamin D also increases intestinal phosphate absorption although the mechanisms are less clear. 3 In the kidney, 1,25-dihydroxyvitamin D augments calcium transport by enhancing the action of PTH and by inducing transient receptor potential vanilloid member 5 and calbindins, which further promote transcellular absorption of calcium. 1,25-dihydroxyvitamin D also acts to enhance 24-hydroxylation and to inhibit 1α-hydroxylation. There is some evidence to suggest that 1,25-dihydroxyvitamin D affects phosphate reabsorption through actions on the sodium phosphate transporter in the proximal tubules, with PTH playing an important role in determining the level of reabsorption. 4 In bone, vitamin D stimulates osteoclasts to cause bone resorption, releasing calcium and phosphate. This is a simplistic summary of the extremely complex and pleotrophic effects of vitamin D in bone, which include both direct and indirect effects on osteoblasts, osteoclasts and osteocytes (reviewed in detail in previous papers 5, 6 Vitamin D may also have an important role in musculoskeletal health beyond bone through direct effects on muscle. Vitamin D deficiency has been associated with increased muscle sway and risk of falls in the elderly (data reviewed in 13 ) although the efficacy of supplementation to reduce falls -particularly in the general population -remains contentious. 14 
NON-CANONICAL ROLES
The widespread tissue expression of VDR has led to the recognition of multiple non-canonical roles for vitamin D, particularly its immunomodulatory properties. Vitamin D promotes innate immunity whilst suppressing adaptive immunity, in addition to anti-inflammatory, anti-mitogenic and anti-tumourigenic effects in vitro and ex vivo.
Exploration of the role of vitamin D in the innate immune system has suggested that vitamin D may have paracrine/autocrine effects in addition to its endocrine actions, through local CYP27B1 conversion of circulating 25-hydroxyvitamin D. Recently, Liu et al. showed that macrophages activated via toll-like receptors increased expression of both CYP27B1 and VDR, with subsequent intracrine induction of cathelicidin expression and enhanced killing of M.tuberculosis. This effect was seen in response to both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D; however, of the two, 25-hydroxyvitamin D was more efficient in microbial killing. 15 These data suggest that "the robustness of the human innate response to microbial challenge is dependent upon the serum 25OHD status of the host". The observation is fascinating given traditional use of sunlight exposure for tuberculosis 16 ; and is of particular relevance when considering the vitamin D status of immunocompromised patients post renal transplantation especially as these patients are advised to avoid excessive sunlight.
Many epidemiological studies have shown an association between vitamin D levels and autoimmune diseases (including type 1 diabetes and multiple sclerosis), cardiovascular disease (CVD) (including inflammation, insulin resistance, hypertension and vascular calcification), 17 chronic infections (such as tuberculosis), malignancy, and mortality. Nonetheless, interventional studies involving vitamin D supplementation have failed to show beneficial cardio-protective, anti-cancer and/or anti-infective effects of vitamin D supplementation in the general population. [18] [19] [20] [21] [22] [23] Further, although many epidemiological studies in the general population have shown an inverse association between 25-hydroxyvitamin D concentration and risk of CVD and all-cause mortality, recent studies have suggested a reverse J-shaped association between 25-hydroxyvitamin D concentration and mortality. In the observational Copenhagen vitamin D cohort study of almost 250 000 subjects from the general population, extremes of serum 25-hydroxyvitamin D concentrations were associated with a higher risk of stroke, major cardiac events and CVD mortality. Compared with a level of 70 nmol/L, a level of 125 nmol/L was associated with an adjusted hazard ratio of 1.3 (95% confidence interval [95%CI] 1.2-1.4) for stroke and CVD mortality whereas 25-hydroxyvitamin D of <12.5 nmol/L was associated with the highest risk of CVD mortality and an adjusted hazard ratio of 2.0 (95%CI 1.8-2.1). These suggest the possibility of an 'optimal' target 25-hydroxyvitamin D range for beneficial health outcomes in the general population. 24 In a cohort study of 1621 older individuals, the associ- 26 and serum levels are several log-orders higher, also aiding accurate measurement. Until recently, there has been a lack of laboratory standardization in the measurement of 25-hydroxyvitamin D concentration. Vitamin D can be measured by liquid chromatography-tandem mass spectrometry (LC-MS) or by automated immunoassays. Although sensitive and specific, LC-MS was expensive and had low sample throughput; in contrast, cheaper high-throughput automated immunoassays were highly variable and not optimally standardized. The development of reference standards using a validated LC-MS method by the US National Institute of Standards and Technology along with regulatory requirements for measurement of 25-hydroxyvitamin D concentration have improved the performance of routine immunoassay methods, and all laboratories in Australia are required to be part of an appropriate external quality assurance programme. Nonetheless, it is advisable that repeat measures be made through the same laboratory when looking for response to treatment. 
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Target levels for serum 25- 29 , (data reviewed in detail in 30 ). However, an adequate calcium intake is necessary to achieve optimal bone health at these vitamin D levels. Further, because of potential seasonal variability in exposure to sunlight and consequent effect on serum 25-hydroxyvitamin D levels, 31 the recommendation for the non-CKD population is that vitamin D levels are >60-70 nmol/L at the end of summer and >50 nmol/L at the end of winter. 
Role of nutritional vitamin D in individuals with CKD
Vitamin D deficiency is highly prevalent in CKD patients and may contribute to the higher risk of CVD in these patients. 17 When estimated glomerular filtration rates (eGFR) falls below 60 mL/min/1.73m 2 , serum 25-hydroxyvitamin D begins to decline as a result of multiple factors, including reduced sun exposure and skin synthesis of cholecalciferol, dietary restrictions, impaired intestinal absorption (of both dietary and supplemental vitamin D) and urinary loss of vitamin D binding protein in proteinuric patients. 34 Several systematic reviews of observational studies and randomized controlled trials (RCTs) have examined the effects of vitamin D compounds on clinical, biochemical, bone and other outcomes in patients with CKD, including dialysis patients and kidney transplant recipients. [35] [36] [37] [38] Although these analyses suggested that vitamin D supplementation was associated with an increase in the 25-hydroxyvitamin D level and decline in PTH, there was no convincing evidence to Lim WH and Duncan EL than a reduction in PTH levels after nutritional vitamin D replacement in vitamin D deficient CKD patients, there were no consistent benefits on other health or biochemical outcomes observed in these RCTs. In addition, the benefits of vitamin D replacement on improving muscle strength and reducing the risk of falls seen in some studies of in the general elderly population has not been shown in patients with CKD. 14, 53, 54 Recommendations of nutritional vitamin D supplementation in chronic kidney disease patients
The target or threshold for nutritional vitamin D supplementation in CKD patients is largely extrapolated from the general population guidelines. The current national (Caring for Australasians with Renal Impairment [CARI]) 55 and international (Kidney Disease: Improving Global Outcomes [KDIGO]) guidelines (http://kdigo.org/home/guidelines) propose several recommendations with regards to the practical use of nutritional vitamin D replacements in patients with CKD, but the level of evidence supporting these recommendations is reasonably weak and based on low-quality studies ( Table 2) . The 2016 KDIGO clinical practice guideline update on the diagnosis, evaluation, prevention and treatment of CKD-MBD has been released for public comment, with final publication expected in 2017 (accessible at http://www.kdigo.org/ clinical_practice_guidelines/CKD-MBD%20Update/KDIGO% 20CKD-MBD%20Update_Public%20Review_Final.pdf).
Changes to the recommendation of use of nutritional vitamin D in the 2016 guideline compared with the 2009 guidelines were limited to the following circumstances: a. patients with CKD Stages 3a-5 not on dialysis, in whom levels of intact PTH were progressively rising or persistently above the upper normal limit for the assay [without a defined optimal target value], in whom vitamin D deficiency is a modifiable risk factor (graded 2C). b. Patients in the first 12 months post-transplantation in individuals with eGFR >30 mL/min per 1.73m 2 and low
BMD (graded 2D)
The document acknowledged the role of nutritional vitamin D deficiency contributing to hypocalcaemia through impaired intestinal calcium absorption; and its contribution to secondary hyperparathyroidism. However, most of the recommendations regarding vitamin D relate to use of calcitriol and/or other vitamin D analogues, and evidence to recommend cholecalciferol was lacking.
Potential for research
There continue to be controversies with regards to the threshold of 25-hydroxyvitamin D concentration to define deficiency or insufficiency; 'optimal' dosing regimens; and whether ethnicity, season or country modify the 'optimal' concentration of 25-hydroxyvitamin D concentration for beneficial health outcomes. Results from meta-analyses of vitamin D supplementation in preventing all-cause mortality, cardiovascular morbidity and malignancy have been underwhelming. Despite these uncertainties with respect to the potential health benefits of nutritional vitamin D, there continues to be considerable interest, with several large scale intervention studies currently involving up to 100 000 participants across the United States, Australia, and Europe. 56 The results of the two largest RCTs using nutritional vitamin D supplementation in the general population may provide more However, in considering this list, we acknowledge that to date evidence from large trial data and/or meta-analyses has not been supportive of a substantive role for vitamin D in determining these outcomes in the non-CKD population. 
